Did IPG Photonics beat or miss consensus estimates last quarter?

What does IPG Photonics do and what are its main business segments?

What is IPG Photonics's latest dividend and current dividend yield?

What were the key takeaways from IPG Photonics’s earnings call?

What were the key takeaways from IPG Photonics's earnings call?

What is IPG Photonics's gross profit margin?

What is the market's earnings forecast for IPG Photonics next quarter?

What is the revenue and EPS growth rate for IPG Photonics year over year?

- **Revenue Growth**: Q3 revenue of $251 million (+11% YoY, ex-divestitures) driven by welding (battery production), cleaning (cleanLASER), and medical solutions. Book-to-bill of 1.0 signals stable demand.
- **Strategic Wins**: FDA-cleared thulium laser system launching in Q4; CROSSBOW directed energy system generating defense and civilian interest. New Huntsville facility to support production.
- **Margin Improvement**: Adjusted gross margin of 39.8% (up 120 bps YoY) due to cost absorption. Tariffs reduce margins by 140 bps, but mitigation strategies (pricing, diversification) expected to ease impact in 2026.
- **Long-Term Growth**: Targeting $5 billion TAM across medical, micromachining, and defense. Urology revenue expected to grow 2-3x over 2-3 years, supported by recurring fiber sales.
- **Q4 Outlook**: Revenue $230-260 million (midpoint -10% YoY), adjusted EPS $0.05-$0.35 (midpoint -40% YoY). Elevated OpEx (~$91 million) reflects strategic investments.

### Core Details - Detail Page

**CEO Summary Section**
- **Revenue Performance**: Q3 revenue of $251 million, flat sequentially and up 11% YoY (excluding divestitures). Book-to-bill ratio of 1.0, indicating stable demand. Key growth drivers include welding (battery production), cleaning (via cleanLASER acquisition), and medical solutions.
- **Strategic Wins**: 
  - FDA clearance for next-gen thulium medical laser system, expected to ship in Q4. This system features StoneSense technology for improved kidney stone removal precision.
  - CROSSBOW directed energy system showcased at DSEI and AUSA, generating interest from defense and civilian customers. New Huntsville, Alabama facility to support production and testing.
- **Long-Term Strategy**: Focus on converting incumbent processes to laser solutions in medical, micromachining, and defense. Targeting $5 billion TAM across these segments, with urology revenue expected to grow 2-3x over 2-3 years.

**CFO Financial Commentary**
- **Financial Highlights**: 
  - GAAP net income of $7 million ($0.18 EPS), adjusted EBITDA of $37 million (top end of guidance).
  - Gross margin improved to 39.8% (39.5% GAAP), driven by cost absorption and lower inventory provisions. Tariffs reduced margins by 140 basis points, consistent with Q3 impact.
  - Operating expenses elevated at $90-92 million due to strategic investments in growth initiatives.
- **Q4 Outlook**: 
  - Revenue: $230-260 million (midpoint $245 million, -10% YoY). 
  - Adjusted EPS: $0.05-$0.35 (midpoint $0.20, -40% YoY). 
  - CapEx expected to remain elevated at ~$100 million due to German manufacturing project, but free cash flow expected to improve post-project completion.

**Q&A Key Highlights**
- **Defense Market**: CROSSBOW system interest spans military and civilian applications (e.g., drone defense at airports). First revenue contributions expected in 2026, with potential for significant growth.
- **Medical Market**: New urology system launch in Q4 positions IPG to gain share in a $2 billion TAM. Recurring revenue from disposable fibers expected to complement system sales.
- **Tariffs and Margin Management**: Tariffs (~140 bps impact) being partially offset by pricing adjustments and supply chain diversification. Gross margin expected to stabilize in 2026 as mitigation strategies take effect.
- **Operating Expenses**: Elevated OpEx reflects investments in medical, micromachining, and defense initiatives, with no near-term reduction expected.


IPG Photonics Corporation (IPGP) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: Q2 revenue of $251M (+10% sequential, +2% YoY) driven by welding, cutting, and advanced applications growth.
- **CROSSBOW Success**: Delivered multiple units to Lockheed Martin, targeting $1B+ directed energy market with scalable, cost-effective solution.
- **Gross Margin Resilience**: 37.8% adjusted margin despite 115bps tariff impact, with operating leverage improving.
- **Q3 Outlook**: Guidance of $225-255M reflects cautious optimism, with tariff mitigation and emerging product (54% of sales) growth.
- **Strategic Investments**: $100M CapEx for capacity, $30M share buybacks, and pipeline of $50-200M M&A opportunities.


**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue of $251M exceeded expectations, up 10% sequentially and 2% YoY (excluding divestitures), marking the first YoY increase since 2022.
- **Materials Processing Recovery**: Sequential growth in welding, cutting, and marking applications, driven by EV battery investments in China and stabilizing industrial demand.
- **Strategic Initiatives**: 
  - **Directed Energy**: Delivered multiple CROSSBOW units to Lockheed Martin for drone defense, showcasing IPG's laser expertise and manufacturing scale.
  - **Medical & Micromachining**: Strong growth in medical urology and micromachining, with Q4 product launches planned.
  - **Tariff Mitigation**: Shifted $10M of at-risk orders to avoid delays, leveraging global supply chain flexibility.
- **Financial Discipline**: Repurchased $30M in shares, maintaining strong balance sheet with $900M in cash.

**【CFO Financial Commentary】**
- **Gross Margin**: 37.3% (flat YoY), with adjusted margin at 37.8% due to improved cost absorption and lower inventory provisions.
- **Operating Expenses**: Elevated by strategic investments, including $100M CapEx for capacity expansion.
- **Q3 Guidance**: Revenue $225-255M, adjusted EBITDA $22-36M, with potential higher tariff impact (115bps in Q2).
- **Cash Flow**: Expect significant operating cash flow improvement in H2, supporting free cash flow growth in 2026.

**【Q&A Key Highlights】**
- **Book-to-Bill**: 1.0 across all regions, reflecting demand stabilization.
- **Directed Energy Market**: Estimated $1B annual spend, with CROSSBOW targeting small drones (Group 1/2). DSEI showcase expected to drive defense and civilian interest.
- **Gross Margin Leverage**: 500bps underabsorption improvement in Q2, with further gains expected from cost reduction initiatives.
- **Customer Sentiment**: Cautious optimism amid macro uncertainty, with PMI and industrial production improvements supporting bookings.


IPG Photonics Corporation (IPGP) Q2 2025 Earnings Call Transcript

- **Emerging Growth Dominance**: >50% of Q1 revenue from medical, micromachining, and advanced apps, up from <40% last year.
- **Tariff Resilience**: $15M shipment delays offset by $927M cash buffer; 145% China tariffs to be neutralized by Q4 2025.
- **Medical Breakthrough**: New urology customer and Q2 bookings set stage for 2026+ revenue surge from thulium laser launch.
- **China EV Recovery**: AMB laser adoption in EV battery welding up 22% QoQ, driven by e-mobility demand.
- **Profitability Edge**: 39.4% gross margin vs. peers' <30%, fueled by differentiated tech and global supply chain control.


**【CEO Summary Section】**
- Q1 revenue of $228 million reflects stabilization across key markets, with book-to-bill ratio >1.0, the strongest in over two years.
- Emerging growth products (medical, micromachining, advanced apps) now account for >50% of sales, driven by new customer wins and product launches.
- China EV battery welding demand rebounded, with AMB laser adoption growing in e-mobility applications.
- Tariffs caused $15M shipment delays, but no cancellations; manufacturing flexibility allows production shifts to mitigate costs.
- R&D investments in AI and laser subsystems position IPG for long-term growth in high-margin markets.

**【CFO Financial Commentary】**
- GAAP net income of $4M ($0.09 EPS) vs. $0.31 adjusted EPS, reflecting $927M cash balance and no debt.
- Gross margin improved to 39.4% (40% adj.), driven by reduced inventory provisions and optimized supply chain.
- Q2 guidance: $210M-$240M revenue (down $15M due to tariffs), adj. EBITDA $16M-$31M, with 150-200bps tariff impact on gross margin.
- Operating expenses to rise through 2025 as R&D and go-to-market investments accelerate growth initiatives.

**【Q&A Key Themes】**
- **Tariff Mitigation**: Moving production to low-tariff regions and selective pricing will offset 145% China tariffs by Q4 2025.
- **Medical Momentum**: New urology customer and Q2 bookings suggest 2026+ revenue ramp from next-gen thulium laser launch.
- **Micromachining Breakthrough**: New product launch doubled Q1 revenue, with strong pipeline for semiconductor and microelectronics apps.
- **Asia Recovery**: China EV battery welding orders up 22% QoQ, driven by AMB laser adoption in e-mobility supply chains.
- **Strategic Acquisitions**: cleanLASER acquisition already contributing to additive manufacturing growth.


IPG Photonics (IPGP)-6 May 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: Q4 revenue $234M (high end of guidance), up sequentially with 38.6% gross margin.
- **Strategic Investments**: $5+ billion TAM in medical, micromachining, and advanced apps; 40kW laser platform to defend cutting market share.
- **Cash Strength**: $930M cash, $74M free cash flow, no debt.
- **2025 Outlook**: Q1 OpEx $82-84M, gross margin 36-39%, targeting 2026+ growth from new products.
- **Key Risks**: Macroeconomic weakness in industrial/EV, <5% China revenue exposure.


**【CEO Overview】**
- Q4 revenue reached $234 million, at the high end of guidance, with sequential growth despite macro challenges in industrial and EV markets.
- Gross margin improved to 38.6% due to cost reductions and inventory management.
- Strategic investments in R&D and acquisitions (e.g., cleanLASER) aim to drive long-term growth in medical, micromachining, and advanced applications with a $5+ billion TAM.
- New high-power fiber laser platform (40kW) launched to compete with low-cost Chinese systems, targeting 2026+ revenue ramp-up.
- Free cash flow remains strong at $74 million, with no debt and $930 million in cash.

**【CFO Financial Breakdown】**
- Q4 GAAP net income: $8 million ($0.18 EPS); Non-GAAP EPS: $0.10 (excluding one-time tax impacts).
- Operating expenses down 5% YoY to $84 million, driven by cost control and Russian divestiture.
- Revenue by region: North America (+6% QoQ), Europe (+5% QoQ), China (-10% QoQ).
- 2025 CapEx guidance: $105-115 million for German manufacturing expansion.
- Q1 2025 outlook: Revenue $210-240 million, gross margin 36-39%, OpEx $82-84 million.

**【Q&A Highlights】**
- **Cutting Market Competition**: New 40kW laser platform enables OEMs to compete with Chinese systems, with <5% China revenue exposure.
- **Medical Growth**: Urology product launch in late 2025, targeting $500+ million in 2026+ revenue.
- **Tariffs Impact**: Flexible manufacturing footprint (U.S., Europe) mitigates tariffs; potential long-term benefit from reshoring incentives.
- **EV Battery Welding**: Strong position in adjustable mode lasers with 100%+ growth in stationary storage.
- **2025 Visibility**: Book-to-bill near 1, with potential Q2 recovery in industrial demand and contributions from new programs.


IPG Photonics (IPGP)-11 Feb 25-2024 Q4 Earnings call transcript

IPG Photonics (IPGP)-29 Oct 24-2024 Q3 Earnings call transcript

IPG Photonics (IPGP)-30 Jul 24-2024 Q2 Earnings call transcript

IPG Photonics (IPGP)-30 Apr 24-2024 Q1 Earnings call transcript

IPG Photonics (IPGP)-13 Feb 24-2023 Q4 Earnings call transcript

IPG Photonics (IPGP)-31 Oct 23-2023 Q3 Earnings call transcript

- **Q2 Results**: Revenue $340M (-10% YoY), driven by welding, cleaning, and e-mobility. Emerging Growth Products (41% of sales) led by AMB and LightWELD lasers.
- **E-Mobility Strength**: EV-related orders robust outside China, with drying systems booked for Q3. China EV investment shifting to cylindrical batteries.
- **Medical Recovery**: Q3 medical sales expected to normalize after inventory adjustment. New Director to accelerate medical growth.
- **Gross Margin Outlook**: Q3 margin 40-42% due to under-absorption; long-term recovery tied to Poland factory and cost optimization.
- **Key Risks**: China cutting competition, macro uncertainty in industrial markets, but e-mobility and medical provide resilience.

**【CEO Summary Section】**
- **Revenue Performance**: Q2 revenue of $340M (-10% YoY) driven by growth in welding, cleaning, 3D printing, and solar cell applications. Emerging Growth Products (41% of sales) saw strong growth in AMB, LightWELD, green, and ultrafast lasers. Cutting sales declined YoY due to China competition but improved sequentially in China, North America, and Japan.
- **E-Mobility Focus**: EV-related sales (e.g., battery welding, drying systems) remained strong outside China, with orders expected to stay robust in Q3. New opportunities in motor assembly and energy storage are emerging.
- **Medical Recovery**: Q2 medical sales were impacted by a large customer inventory adjustment but expected to normalize in Q3. New Director Kolleen Kennedy will support medical growth.
- **Sustainability Initiatives**: High-efficiency ECO lasers (50%+ wall-plug efficiency), laser cleaning (reduces chemicals and water), and drying systems are gaining traction in e-mobility and industrial applications.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $62M ($1.31 EPS), operating margin 21.2%. Gross margin 43.4% (-230bps YoY) due to cost headwinds, partially offset by manufacturing efficiency gains. FX headwinds reduced revenue by ~2%.
- **Revenue Breakdown**: Materials processing (-8% YoY), other applications (-23% YoY). High-power CW lasers (-10%), ultra-high-power (>6kW) lasers 50% of CW sales. Medium-power lasers (+18%), QCW (-2%).
- **Regional Performance**: North America (-11%), Europe (+4%), China (-28%). Japan and South Korea showed resilience.
- **Outlook**: Q3 revenue $300-330M, gross margin 40-42%, EPS $0.85-1.15. Book-to-bill <1, macro uncertainty persists, but e-mobility and medical demand provide offsets.

**【Q&A Key Highlights】**
- **Cutting Market**: China competition weighed on flat-sheet cutting, but sequential improvement in China, NA, Japan. Cutting <10% of total sales.
- **Gross Margin**: Sequential improvement in Q2, but Q3 under-absorption due to lower revenue. Long-term margin recovery tied to Poland factory and cost optimization.
- **EV Demand**: China EV investment slowed (prismatic cells), but cylindrical batteries and storage are growing. North America/Europe EV orders strong, with drying systems booked for Q3.
- **Inventory Management**: Target <200 days inventory (currently ~200 days). Poland and Italy factories reducing component costs.
- **Consumer Electronics**: Minimal impact, with QCW sales down YoY. Additive manufacturing gaining traction in Europe and China.
- **Europe Resilience**: Welding and cleaning applications held up despite weak PMIs. Germany economy weak, but order flow remains.


IPGP

IPGP fundamentals

Earnings Call

You can ask Aime